Fu; Wenlang

Patent Applications and Registrations

Patent applications and USPTO patent grants for Fu; Wenlang.The latest application filed is for "factor xi activation inhibitors".

Company Profile

1.10.17

Fu; Wenlang - Madison NJ
Fu; Wenlang - Rahway NJ
Fu; Wenlang - Florham Park NJ US
Fu; Wenlang - Milford CT
Fu; Wenlang - Hamden CT

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Factor Xi Activation Inhibitors App 20220235033 - Hicks; Jacqueline D. ; et al.	2022-07-28
Antiviral oxime phosphoramide compounds Grant 10,450,335 - Fu , et al. Oc	2019-10-22
Antiviral Oxime Phosphoramide Compounds App 20180362563 - Fu; Wenlang ; et al.	2018-12-20
Method for rapidly evaluating performance of short interfering RNA with novel chemical modifications Grant 9,512,426 - Butora , et al. December 6, 2	2016-12-06
Hydroxymethylaryl-substituted pyrrolotriazines as ALK1 inhibitors Grant 9,040,691 - Klar , et al. May 26, 2	2015-05-26
Method For Rapidly Evaluating Performance Of Short Interfering Rna With Novel Chemical Modifications App 20150132761 - Butora; Gabor ; et al.	2015-05-14
Method for rapidly evaluating performance of short interfering RNA with novel chemical modifications Grant 8,877,439 - Butora , et al. November 4, 2	2014-11-04
Hydroxymethylaryl-substituted Pyrrolotriazines As Alk1 Inhibitors App 20140256718 - Klar; Jurgen ; et al.	2014-09-11
Pyrrolotriazine Derivatives Useful For Treating Hyper-proliferative Disorders And Diseases Associated With Angiogenesis App 20130225809 - Dixon; Julie A. ; et al.	2013-08-29
Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis Grant 8,338,595 - Dixon , et al. December 25, 2	2012-12-25
Method For Rapidly Evaluating Performance Of Short Interfering RNA With Novel Chemical Modifications App 20120252027 - Butora; Gabor ; et al.	2012-10-04
Urea Compounds Useful In The Treatment Of Cancer App 20110195110 - Smith; Roger ; et al.	2011-08-11
Pyrimidine Derivatives for Treatment of Hyperproliferative Disorders App 20110098301 - Dixon; Julie A. ; et al.	2011-04-28
Pyrrolotriazine Derivatives Useful For Treating Hyper-proliferative Disorders And Diseases Associated With Angiogenesis App 20100075958 - Dixon; Julie A. ; et al.	2010-03-25
Pyrimidine Derivatives For Treatment Of Hyperproliferative Disorders App 20100075967 - Dixon; Julie A. ; et al.	2010-03-25
Pyrimidine derivatives for treatment of hyperproliferative disorders Grant 7,678,804 - Dixon , et al. March 16, 2	2010-03-16
Pyrimidine Derivatives App 20090286785 - Nagarathnam; Dhanapalan ; et al.	2009-11-19
Pyrimidine Derivatives App 20090258888 - Nagarathnam; Dhanapalan ; et al.	2009-10-15
Pyrimidine derivatives for treatment of hyperproliferative disorders Grant 7,582,645 - Dixon , et al. September 1, 2	2009-09-01
Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis Grant 7,563,791 - Dixon , et al. July 21, 2	2009-07-21
Pyrrolotriazine Derivatives Useful For Treating Hyper-Proliferative Disorders And Diseases Associated With Angiogenesis App 20070208013 - Dixon; Julie A. ; et al.	2007-09-06
Pyrimidine derivatives for treatment of hyperproliferative disorders App 20070117817 - Dixon; Julie A. ; et al.	2007-05-24
Pyrimidine derivatives for treatment of hyperproliferative disorders App 20050277640 - Dixon, Julie A. ; et al.	2005-12-15
3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors App 20040267017 - Bierer, Donald E ; et al.	2004-12-30

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.